An wins ASPET scientific achievement award
The American Society for Pharmacology and Experimental Therapeutics (ASPET) has named Zhiqiang An, PhD, professor and Robert A. Welch Distinguished University Chair in Chemistry and vice president of Drug Discovery, as the winner of its 2024 Scientific Achievement Award in Drug Discovery and Development. The…
Hancock’s Headlines: Texas Therapeutics Institute
When the COVID pandemic hit, the Texas Therapeutics Institute sprung into action to develop therapies for patients suffering from the virus. Not only have they developed drugs to help fight COVID, but they are also developing neurological drugs to help…
New antibody shows therapeutic effects in mice with Alzheimer’s disease (UTHealth Houston News)
Research led by senior author Zhiqiang An, PhD, professor and Robert A. Welch Distinguished University Chair in Chemistry at McGovern Medical School at UTHealth Houston, found that a tetra-variable domain antibody targeting the triggering receptor expressed on myeloid 2 (TREM2) –…
An earns National Academy of Inventors fellowship
Zhiqiang An, PhD, professor and director of the Texas Therapeutics Institute of the Brown Foundation Institute of Molecular Medicine and Graduate School faculty member, has been named a fellow of the National Academy of Inventors (NAI), the organization announced Dec….
GW Researchers Identify Molecule That Blocks Immune Cells from Killing Breast Tumors
George Washington University researchers have identified a key molecule in certain kinds of breast cancers that prevent immune cells from entering tumors and killing the cancer cells inside—a finding that could pave the way toward new treatments for some aggressive…
Research on antibody-drug conjugates shows promise in fighting breast cancer
Research from the lab of Kyoji Tsuchikama, PhD, assistant professor in the Texas Therapeutics Institute at The Brown Foundation Institute of Molecular Medicine, on a new potential treatment for combating breast cancer has been published in the June edition of Nature Communications. “Breast tumors…
Could a Nasal Spray of Designer Antibodies Help to Beat COVID-19? NIH Director’s Blog
There are now several monoclonal antibodies, identical copies of a therapeutic antibody produced in large numbers, that are authorized for the treatment of COVID-19. But in the ongoing effort to beat this terrible pandemic, there’s plenty of room for continued…
Antibody-laden nasal spray could provide COVID protection — and treatment
A nasal spritz of a designer antibody offers strong protection against variants of the coronavirus SARS-CoV-2 — at least in mice1. Since the early days of the pandemic, scientists have been developing antibodies as treatments for COVID-19. Today, several such…
New IgM antibodies administered intranasally to fight COVID-19 more potent than commonly used ones
A nasal therapy, built upon on the application of a new engineered IgM antibody therapy for COVID-19, was more effective than commonly used IgG antibodies at neutralizing the COVID-19 virus in animal models, according to research recently published by The…
Study finds why some cancer drugs may be ineffective
A possible explanation for why many cancer drugs that kill tumor cells in mouse models won’t work in human trials has been found by researchers with The University of Texas Health Science Center at Houston (UTHealth) School of Biomedical Informatics…